GSK Highlights Easy Pen Delivery Of Albiglutide As FDA Begins Review

The GLP-1 class is set for huge growth in the diabetes market, but competition is going to be tough. GlaxoSmithKline explains why its newly submitted once-weekly GLP-1 agonist albiglutide has what it takes to succeed.

More from Clinical Trials

More from R&D